A Pathophysiological Model of Parkinson's Disease Based on Microvascular Flow Disturbance and Leukocyte-Mediated

Emilio Fernández-Espejo1,2, Fernando Rodríguez de Fonseca2

  • 1Royal College of Physicians of Seville, 41013 Seville, Spain.

PubMed

Insights

Idiopathic Parkinson's disease may stem from altered microvascular flow in critical brain regions. This leads to immune cell activation, oxidative stress, and alpha-synuclein aggregation, driving neurodegeneration.

Area of Science:

  • Neuroscience
  • Pathology
  • Immunology

Background:

  • Idiopathic Parkinson's disease (PD) pathology is complex and not fully understood.
  • Pigmented neurons expressing neuromelanin and lipofuscin are implicated in PD.
  • The role of microvascular dysfunction and immune responses in PD pathogenesis requires further investigation.

Purpose of the Study:

  • To propose a novel hypothesis for the pathogenesis of idiopathic Parkinson's disease.
  • To elucidate the potential role of microvascular flow alterations at specific neural "critical points" in PD onset.
  • To explore the interplay between hypoxia-ischemia, immune cell activation, oxidative stress, and alpha-synuclein aggregation in PD.

Main Methods:

  • This study presents a hypothesis based on existing literature and proposed mechanisms.
  • It integrates concepts of neurovascular coupling, neuroinflammation, and protein misfolding.
  • The hypothesis focuses on "critical points" in the nervous system with pigmented cells.

Main Results:

  • Altered microvascular flow at "critical points" (e.g., olfactory bulb, amygdala) can cause hypoxia-ischemia.
  • Hypoxia-ischemia triggers leukocyte activation and peripheral immune cell infiltration.
  • This leads to oxidative stress, promoting neuromelanin, lipofuscin, and alpha-synuclein accumulation and misfolding.

Conclusions:

  • A proposed "amplification" mechanism involving pigmented neurons and immune responses may explain PD onset.
  • This hypothesis highlights the crucial role of "critical points" in initiating PD pathology.
  • The findings suggest potential new therapeutic targets for early prevention and biomarker development in Parkinson's disease.